IP Library Granted Patent US 12,702,850
Granted Patent B2
US 12,702,850 · App. 18/405,548 · Granted Aug 11, 2026

Methods and systems for distinguishing VT from VF

Inventor: Joseph L. Sullivan (Kirkland, WA)
Assignee: West Affum Holdings DAC
A61N1/3987A61B5/0245A61N1/025A61N1/046A61N1/3904A61N1/3925A61N1/0484
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,702,850
App. No.
18/405,548
Granted
Aug 11, 2026
Kind
B2
Abstract

Embodiments of a wearable cardioverter defibrillator (WCD) system include a support structure for wearing by an ambulatory patient and at least one processor. When worn, the support structure maintains electrodes on the patient's body, and using the patient's ECG received via the electrodes, the processor determines widths of the QRS complexes, consistency of the QRS complexes, and/or heart rate and uses these determinations to make no-shock, delay-shock, and shock decisions. Shock decisions can be made for heart rates lower than a VF threshold.

Claims (62)

1 . A method for a defibrillator system to selectively deliver a shock to a patient, the defibrillator system including an energy storage module configured to store an electrical charge, a plurality of electrodes, and one or more processors, the method comprising:

receiving at least one electrocardiogram (ECG) signal of the patient via one or more of the plurality of electrodes;

identifying QRS complexes of the received ECG signal;

measuring width values of the QRS complexes and a heart rate from the QRS complexes;

determining a consistency metric of the QRS complexes, wherein determining the consistency metric further comprises:

detecting a goodness point in each of the QRS complexes of the received ECG signal, and

determining an average of the goodness points of the QRS complexes;

responsive, at least in part, to the width values, the heart rate, and the consistency metric, classifying the received ECG signal into one of a plurality of rhythm types, the plurality of rhythm types including at least a non-shockable rhythm type, a ventricular fibrillation (VF) rhythm type, and a ventricular tachycardia (VT) rhythm type; and

discharging, responsive to an ECG signal being classified into the VF rhythm type, at least some of the stored electrical charge through at least one of the plurality of electrodes to deliver the shock to the patient.

2 . The method of claim 1 , wherein classifying the received ECG signal into one of the plurality of rhythm types comprises classifying the received ECG signal into the VF rhythm type in response to the heart rate being greater than a VF heart rate threshold and/or the heart rate being above a VT heart rate threshold and the consistency metric meeting a disorganized criterion.

3 . The method of claim 2 , further comprising classifying the received ECG signal into the VF rhythm type in response to the heart rate being greater than the VF heart rate threshold and an average of the width values being above a width threshold and/or the heart rate being above a VT heart rate threshold and the consistency metric meeting a disorganized criterion and the average of the width values being above the width threshold.

4 . The method of claim 3 , wherein the VF heart rate threshold ranges from 150 beats per minute (BPM) to 250 BPM, the VT heart rate threshold ranges from 130 BPM to 200 BPM, and the width threshold ranges from 80 milliseconds (ms) to 160 ms.

5 . The method of claim 2 , further comprising:

prompting a user or a bystander to initiate manual delivery of the shock to the patient responsive to the heart rate being below the VT heart rate threshold and the width values of the QRS complexes being below and an average of the width values being below a width threshold.

6 . The method of claim 1 , further comprising:

responsive to the ECG signal of the patient classified in the VT rhythm type for an entirety of a predetermined time period, discharging at least some of the stored electrical charge through at least one of the plurality of electrodes to deliver the shock to the patient; and

responsive to the ECG signal of the patient being reclassified into the non-shockable rhythm type during the predetermined time period, not discharging any of the stored electrical charge during the predetermined time period.

7 . The method of claim 6 , further comprising:

responsive to the ECG signal of the patient being reclassified into the VF rhythm type during the predetermined time period, discharging at least some of the stored electrical charge through at least one of the plurality of electrodes to deliver the shock to the patient during the predetermined time period.

8 . The method of claim 1 , further comprising:

determining whether one or more delay shock criteria is met based on the heart rate, the width values, and the consistency metric; and

in response to a determination that one or more delay shock criteria is met, monitoring the ECG signal of the patient for a predetermined time period after the received ECG signal was classified into the VT rhythm type.

9 . The method of claim 8 , wherein determining whether the one or more delay shock criteria is met comprises determining whether an index value, derived from the heart rate and the width values, is greater than a predetermined index threshold or is less than the predetermined index threshold.

10 . The method of claim 9 , wherein determining whether the one or more delay shock criteria is met further comprises determining whether the consistency metric is greater than a predetermined disorganized threshold or the consistency metric is less than the predetermined disorganized threshold.

11 . The method of claim 10 , further comprising:

responsive to the index value being less than the predetermined index threshold, determining that one of the one or more delay shock criteria is met.

12 . The method of claim 10 , further comprising:

responsive to the index value being greater than the predetermined index threshold and the consistency metric being less than the predetermined disorganized threshold, discharging at least some of the stored electrical charge through at least one of the plurality of electrodes to deliver the shock to the patient.

13 . The method of claim 1 , further comprising:

determining the heart rate of the patient from at least one heart rate sensor,

wherein classifying the received ECG signal into one of the plurality of rhythm types is further responsive at least in part to the determined heart rate.

14 . A method for a wearable cardioverter defibrillator (WCD) system to deliver a shock to a patient, the WCD system including a support structure, an energy storage module configured to store an electrical charge, a plurality of electrodes coupled with the support structure, and one or more processors, the method comprising:

receiving at least one electrocardiogram (ECG) signal of the patient wearing the support structure, wherein the at least one ECG signal is received via one or more of the plurality of electrodes;

identifying QRS complexes of the received ECG signal;

measuring width values of the QRS complexes and a heart rate from the QRS complexes;

determining a consistency metric of the QRS complexes, wherein determining the consistency metric further comprises:

detecting a goodness point in each of the QRS complexes of the received ECG signal, and

determining an average of the goodness points of the QRS complexes;

responsive, at least in part, to the width values, the heart rate, and the consistency metric, classifying the received ECG signal into one of a plurality of rhythm types, the plurality of rhythm types including at least a non-shockable rhythm type, a ventricular fibrillation (VF) rhythm type, and a ventricular tachycardia (VT) rhythm type; and

discharging, responsive to an ECG signal being classified into the VF rhythm type, at least some of the stored electrical charge through at least one of the plurality of electrodes to deliver the shock to the patient.

15 . The method of claim 14 , wherein classifying the received ECG signal into one of the plurality of rhythm types comprises classifying the received ECG signal into the VF rhythm type in response to the heart rate being greater than a VF heart rate threshold and/or the heart rate being above a VT heart rate threshold and the consistency metric meeting a disorganized criterion.

16 . The method of claim 15 , further comprising classifying the received ECG signal into the VF rhythm type in response to the heart rate being greater than the VF heart rate threshold and an average of the width values being above a width threshold and/or the heart rate being above a VT heart rate threshold and the consistency metric meeting a disorganized criterion and the average of the width values being above the width threshold.

17 . The method of claim 16 , wherein the VF heart rate threshold ranges from 150 beats per minute (BPM) to 250 BPM, the VT heart rate threshold ranges from 130 BPM to 200 BPM, and the width threshold ranges from 80 milliseconds (ms) to 160 ms.

18 . The method of claim 15 , further comprising:

prompting a user or a bystander to initiate manual delivery of the shock to the patient responsive to the heart rate being below the VT heart rate threshold and the width values of the QRS complexes being below and an average of the width values being below a width threshold.

19 . The method of claim 14 , further comprising:

determining whether one or more delay shock criteria is met based on the heart rate, the width values, and the consistency metric; and

in response to a determination that one or more delay shock criteria is met, monitoring the ECG signal of the patient for a predetermined time period after the received ECG signal was classified into the VT rhythm type.

20 . The method of claim 19 , wherein determining whether the one or more delay shock criteria is met comprises determining whether an index value, derived from the heart rate and the width values, is greater than a predetermined index threshold or is less than the predetermined index threshold.

21 . The method of claim 20 , wherein determining whether the one or more delay shock criteria is met further comprises determining whether the consistency metric is greater than a predetermined disorganized threshold or the consistency metric is less than the predetermined disorganized threshold.

22 . The method of claim 21 , further comprising:

responsive to the index value being less than the predetermined index threshold, determining that one of the one or more delay shock criteria is met.

23 . The method of claim 21 , further comprising:

responsive to the index value being greater than the predetermined index threshold and the consistency metric being less than the predetermined disorganized threshold, discharging at least some of the stored electrical charge through at least one of the plurality of electrodes to deliver the shock to the patient.

24 . The method of claim 14 , further comprising:

responsive to the ECG signal of the patient classified in the VT rhythm type for an entirety of a predetermined time period, discharging at least some of the stored electrical charge through at least one of the plurality of electrodes to deliver the shock to the patient; and

responsive to the ECG signal of the patient being reclassified into the non-shockable rhythm type during the predetermined time period, not discharging any of the stored electrical charge during the predetermined time period.

25 . The method of claim 24 , further comprising:

responsive to the ECG signal of the patient being reclassified into the VF rhythm type during the predetermined time period, discharging at least some of the stored electrical charge through at least one of the plurality of electrodes to deliver the shock to the patient during the predetermined time period.

26 . The method of claim 14 , further comprising:

determining the heart rate of the patient from at least one heart rate sensor,

wherein classifying the received ECG signal into one of the plurality of rhythm types is further responsive at least in part to the determined heart rate.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 10, 2024
From: PHYSIO-CONTROL DEVELOPMENT CO., LLC
To: WEST AFFUM HOLDINGS CORP.
Reel/Frame 067949/0146 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 10, 2024
From: WEST AFFUM HOLDINGS CORP
To: WEST AFFUM HOLDINGS DESIGNATED ACTIVITY COMPANY
Reel/Frame 067950/0019 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 1, 2024
From: SULLIVAN, JOSEPH L.
To: PHYSIO-CONTROL DEVELOPMENT CO., LLC
Reel/Frame 066968/0620 →
Continuity (6)
Continuation 16554410 · Aug 28, 2019
Continuation In Part 16366313 · Mar 27, 2019
Division 16268870 · Feb 6, 2019
Provisional Application 62660822 · Apr 20, 2018
Provisional Application 62630398 · Feb 14, 2018
Related Publication 20240157162A1 · May 16, 2024
References Cited (215)
US 3724455A · Unger · 1973 [cited by applicant]
US 4291699A · Geddes et al. · 1981 [cited by applicant]
US 4583524A · Hutchins · 1986 [cited by applicant]
US 4617938A · Shimoni et al. · 1986 [cited by applicant]
US 4619265A · Morgan et al. · 1986 [cited by applicant]
US 4895151A · Grevis et al. · 1990 [cited by applicant]
US 4928690A · Heilman et al. · 1990 [cited by applicant]
US 4955381A · Way et al. · 1990 [cited by applicant]
US 5078134A · Heilman et al. · 1992 [cited by applicant]
US 5228449A · Christ et al. · 1993 [cited by applicant]
US 5348008A · Bornn et al. · 1994 [cited by applicant]
US 5353793A · Bornn · 1994 [cited by applicant]
US RE34800E · Hutchins · 1994 [cited by applicant]
US 5376104A · Sakai et al. · 1994 [cited by applicant]
US 5381803A · Herleikson et al. · 1995 [cited by applicant]
US 5394892A · Kenny et al. · 1995 [cited by applicant]
US 5405362A · Kramer et al. · 1995 [cited by applicant]
US 5425749A · Adams · 1995 [cited by applicant]
US 5474574A · Payne et al. · 1995 [cited by applicant]
US 5554174A · Causey, III · 1996 [cited by applicant]
US 5601612A · Gliner et al. · 1997 [cited by applicant]
US 5630834A · Bardy · 1997 [cited by applicant]
US 5662690A · Cole et al. · 1997 [cited by applicant]
US 5709215A · Perttu et al. · 1998 [cited by applicant]
US 5769872A · Lopin et al. · 1998 [cited by applicant]
US 5782878A · Morgan et al. · 1998 [cited by applicant]
US 5792204A · Snell · 1998 [cited by applicant]
US 5803927A · Cameron et al. · 1998 [cited by applicant]
US 5819007A · Elghazzawi · 1998 [cited by examiner]
US 5902249A · Lyster · 1999 [cited by applicant]
US 5913685A · Hutchins · 1999 [cited by applicant]
US 5944669A · Kaib · 1999 [cited by applicant]
US 6047203A · Sackner et al. · 2000 [cited by applicant]
US 6065154A · Hulings et al. · 2000 [cited by applicant]
US 6068651A · Brandell · 2000 [cited by applicant]
US 6108197A · Janik · 2000 [cited by applicant]
US 6148233A · Owen et al. · 2000 [cited by applicant]
US 6201992B1 · Freeman · 2001 [cited by applicant]
US 6263238B1 · Brewer et al. · 2001 [cited by applicant]
US 6287328B1 · Snyder et al. · 2001 [cited by applicant]
US 6304780B1 · Owen et al. · 2001 [cited by applicant]
US 6319011B1 · Motti et al. · 2001 [cited by applicant]
US 6334070B1 · Nova et al. · 2001 [cited by applicant]
US 6351671B1 · Myklebust et al. · 2002 [cited by applicant]
US 6356785B1 · Snyder et al. · 2002 [cited by applicant]
US 6427083B1 · Owen et al. · 2002 [cited by applicant]
US 6529875B1 · Nakajima et al. · 2003 [cited by applicant]
US 6546285B1 · Owen et al. · 2003 [cited by applicant]
US 6671545B2 · Fincke · 2003 [cited by applicant]
US 6681003B2 · Linder et al. · 2004 [cited by applicant]
US 6694187B1 · Freeman · 2004 [cited by applicant]
US 6762917B1 · Verbiest et al. · 2004 [cited by applicant]
US 6941168B2 · Girouard · 2005 [cited by applicant]
US 7065401B2 · Worden · 2006 [cited by applicant]
US 7149576B1 · Baura et al. · 2006 [cited by applicant]
US 7336994B2 · Hettrick et al. · 2008 [cited by applicant]
US 7379771B2 · Kovac · 2008 [cited by examiner]
US 7460900B1 · Gill et al. · 2008 [cited by applicant]
US 7559902B2 · Ting et al. · 2009 [cited by applicant]
US 7865238B2 · Brink · 2011 [cited by applicant]
US 7870761B2 · Valentine et al. · 2011 [cited by applicant]
US 7894894B2 · Stadler et al. · 2011 [cited by applicant]
US 7974689B2 · Volpe et al. · 2011 [cited by applicant]
US 8024037B2 · Kumar · 2011 [cited by applicant]
US 8036746B2 · Sanders · 2011 [cited by applicant]
US 8135462B2 · Owen et al. · 2012 [cited by applicant]
US 8140154B2 · Donnelly et al. · 2012 [cited by applicant]
US 8369944B2 · Macho et al. · 2013 [cited by applicant]
US 8548557B2 · Garstka et al. · 2013 [cited by applicant]
US 8615295B2 · Savage et al. · 2013 [cited by applicant]
US 8644925B2 · Volpe et al. · 2014 [cited by applicant]
US 8825154B2 · Jorgenson et al. · 2014 [cited by applicant]
US 8838235B2 · Cowan et al. · 2014 [cited by applicant]
US 8897860B2 · Volpe et al. · 2014 [cited by applicant]
US 8904214B2 · Volpe et al. · 2014 [cited by applicant]
US 8965500B2 · Macho et al. · 2015 [cited by applicant]
US 8996101B2 · Zhang et al. · 2015 [cited by applicant]
US 9008801B2 · Kaib et al. · 2015 [cited by applicant]
US 9089685B2 · Sullivan et al. · 2015 [cited by applicant]
US 9131901B2 · Volpe et al. · 2015 [cited by applicant]
US 9132267B2 · Kaib · 2015 [cited by applicant]
US 9408548B2 · Volpe et al. · 2016 [cited by applicant]
US 9454219B2 · Volpe et al. · 2016 [cited by applicant]
US 9533165B1 · Gunderson · 2017 [cited by applicant]
US 9592403B2 · Sullivan · 2017 [cited by applicant]
US 9757579B2 · Foshee, Jr. et al. · 2017 [cited by applicant]
US 9757581B2 · Sullivan et al. · 2017 [cited by applicant]
US 10016614B2 · Sullivan · 2018 [cited by applicant]
US 10322291B2 · Medema et al. · 2019 [cited by applicant]
US 11160990B1 · Sullivan et al. · 2021 [cited by applicant]
US 11331508B1 · Cowan et al. · 2022 [cited by applicant]
US 20030158593A1 · Heilman et al. · 2003 [cited by applicant]
US 20030187479A1 · Thong · 2003 [cited by examiner]
US 20040049117A1 · Ideker et al. · 2004 [cited by applicant]
US 20040220623A1 · Hess · 2004 [cited by applicant]
US 20040230105A1 · Geva et al. · 2004 [cited by applicant]
US 20050107833A1 · Freeman et al. · 2005 [cited by applicant]
US 20050107834A1 · Freeman et al. · 2005 [cited by applicant]
US 20050131476A1 · Kim et al. · 2005 [cited by applicant]
US 20060017575A1 · McAdams · 2006 [cited by applicant]
US 20060173364A1 · Clancy et al. · 2006 [cited by applicant]
US 20070179539A1 · DeGroot et al. · 2007 [cited by applicant]
US 20070203418A1 · Starc · 2007 [cited by examiner]
US 20080208070A1 · Snyder et al. · 2008 [cited by applicant]
US 20080215103A1 · Powers et al. · 2008 [cited by applicant]
US 20080306560A1 · Macho et al. · 2008 [cited by applicant]
US 20080312708A1 · Snyder · 2008 [cited by applicant]
US 20080312709A1 · Volpe et al. · 2008 [cited by applicant]
US 20090005827A1 · Weintraub et al. · 2009 [cited by applicant]
US 20090018595A1 · Bharmi et al. · 2009 [cited by applicant]
US 20100007413A1 · Herleikson et al. · 2010 [cited by applicant]
US 20100114248A1 · Donofrio et al. · 2010 [cited by applicant]
US 20100298899A1 · Donnelly et al. · 2010 [cited by applicant]
US 20100331904A1 · Warren et al. · 2010 [cited by applicant]
US 20110022105A9 · Owen et al. · 2011 [cited by applicant]
US 20110202101A1 · Tan et al. · 2011 [cited by applicant]
US 20110288604A1 · Kaib et al. · 2011 [cited by applicant]
US 20110288605A1 · Kaib et al. · 2011 [cited by applicant]
US 20120022355A1 · Byrd et al. · 2012 [cited by applicant]
US 20120059270A1 · Grunwald · 2012 [cited by applicant]
US 20120108911A1 · Drysdale et al. · 2012 [cited by applicant]
US 20120112903A1 · Kaib et al. · 2012 [cited by applicant]
US 20120144551A1 · Guldalian · 2012 [cited by applicant]
US 20120150008A1 · Kaib et al. · 2012 [cited by applicant]
US 20120158075A1 · Kaib et al. · 2012 [cited by applicant]
US 20120265265A1 · Razavi et al. · 2012 [cited by applicant]
US 20120277638A1 · Skelton et al. · 2012 [cited by applicant]
US 20120283794A1 · Kaib et al. · 2012 [cited by applicant]
US 20120293323A1 · Kaib et al. · 2012 [cited by applicant]
US 20120302860A1 · Volpe et al. · 2012 [cited by applicant]
US 20120310315A1 · Savage et al. · 2012 [cited by applicant]
US 20120316611A1 · Armoundas · 2012 [cited by examiner]
US 20130085538A1 · Volpe et al. · 2013 [cited by applicant]
US 20130231711A1 · Kaib · 2013 [cited by applicant]
US 20130245388A1 · Rafferty et al. · 2013 [cited by applicant]
US 20130274565A1 · Langer et al. · 2013 [cited by applicant]
US 20130317852A1 · Worrell et al. · 2013 [cited by applicant]
US 20130325078A1 · Whiting et al. · 2013 [cited by applicant]
US 20140025131A1 · Sullivan et al. · 2014 [cited by applicant]
US 20140025132A1 · Libbus et al. · 2014 [cited by applicant]
US 20140070957A1 · Longinotti-Buitoni et al. · 2014 [cited by applicant]
US 20140081162A1 · Snell · 2014 [cited by examiner]
US 20140150781A1 · Capua et al. · 2014 [cited by applicant]
US 20140163395A1 · Sapp, Jr. · 2014 [cited by examiner]
US 20140163663A1 · Poddar et al. · 2014 [cited by applicant]
US 20140207204A1 · Halperin · 2014 [cited by examiner]
US 20140324112A1 · Macho et al. · 2014 [cited by applicant]
US 20140378812A1 · Saroka et al. · 2014 [cited by applicant]
US 20150037636A1 · Amsler et al. · 2015 [cited by applicant]
US 20150039053A1 · Kaib et al. · 2015 [cited by applicant]
US 20150105835A1 · Thakur et al. · 2015 [cited by applicant]
US 20150265845A1 · Sullivan et al. · 2015 [cited by applicant]
US 20150273227A1 · Zhang et al. · 2015 [cited by applicant]
US 20150273229A1 · Zhang et al. · 2015 [cited by applicant]
US 20150297107A1 · Sullivan et al. · 2015 [cited by applicant]
US 20150328472A1 · Sullivan et al. · 2015 [cited by applicant]
US 20160000349A1 · Sullivan et al. · 2016 [cited by applicant]
US 20160004831A1 · Carlson et al. · 2016 [cited by applicant]
US 20160007877A1 · Felix et al. · 2016 [cited by applicant]
US 20160015329A1 · Kohlrausch et al. · 2016 [cited by applicant]
US 20160067514A1 · Sullivan · 2016 [cited by examiner]
US 20160074667A1 · Sullivan et al. · 2016 [cited by applicant]
US 20160082277A1 · Foshee, Jr. · 2016 [cited by examiner]
US 20160106332A1 · Takeshima · 2016 [cited by examiner]
US 20160121100A1 · Crone et al. · 2016 [cited by applicant]
US 20160220833A1 · Tan et al. · 2016 [cited by applicant]
US 20160235320A1 · Sarkar et al. · 2016 [cited by applicant]
US 20160278698A1 · Freeman et al. · 2016 [cited by applicant]
US 20160331984A1 · Firoozabadi · 2016 [cited by examiner]
US 20160353996A1 · Fink · 2016 [cited by examiner]
US 20170056682A1 · Kumar et al. · 2017 [cited by applicant]
US 20170157416A1 · Medema et al. · 2017 [cited by applicant]
US 20170225001A1 · Zaidi et al. · 2017 [cited by applicant]
US 20170252571A1 · Dascoli et al. · 2017 [cited by applicant]
US 20180028083A1 · Greenhut et al. · 2018 [cited by applicant]
US 20180093102A1 · Sullivan et al. · 2018 [cited by applicant]
US 20180116537A1 · Sullivan et al. · 2018 [cited by applicant]
US 20180117299A1 · Gustavson et al. · 2018 [cited by applicant]
US 20180153765A1 · Freeman et al. · 2018 [cited by applicant]
US 20180184933A1 · Sullivan et al. · 2018 [cited by applicant]
US 20180185662A1 · Foshee, Jr. et al. · 2018 [cited by applicant]
US 20180221648A1 · Gustavson et al. · 2018 [cited by applicant]
US 20180264279A1 · Kim et al. · 2018 [cited by applicant]
US 20180318593A1 · Sullivan · 2018 [cited by applicant]
US 20190030351A1 · Sullivan et al. · 2019 [cited by applicant]
US 20190030352A1 · Sullivan et al. · 2019 [cited by applicant]
US 20200164217A1 · Sullivan · 2020 [cited by applicant]
US 20220032077A1 · Sullivan et al. · 2022 [cited by applicant]
US 20230023203A1 · Sullivan · 2023 [cited by applicant]
CA 2942933A1 · 2015 [cited by applicant]
CN 103405851A · 2013 [cited by applicant]
DE 10159296A1 · 2003 [cited by examiner]
WO 9839061A2 · 1998 [cited by applicant]
WO WO02058536A2 · 2002 [cited by examiner]
U.S. Appl. No. 62/630,398, filed Feb. 14, 2018, Sullivan. [cited by applicant]
Corrected Notice of Allowability issued on Aug. 9, 2021, to U.S. Appl. No. 16/382,575. [cited by applicant]
Corrected Notice of Allowability issued on Jul. 23, 2021, to U.S. Appl. No. 16/382,575. [cited by applicant]
Duncker et al. “Real-world Experience of 355 Consecutive Patients with a Wearable Cardioverter/Debrillator—Single Centre Analysis” Europace 2017, No. 19 Supplemental 3, iii304. [cited by applicant]
EPO Search Report mailed Dec. 19, 2018 on EP Application No. 1816221.0-1224. [cited by applicant]
EPO Search report mailed Sep. 27, 2018 on EP Application 18186229.3-1224. [cited by applicant]
European Search Report of European Application 16202067.1-1666, dated Apr. 25, 2017. [cited by applicant]
First Office action and Search Report issued on Aug. 30, 2018, to CN Patent Application No. 2016111063501. [cited by applicant]
Heartstart MRx and XL AED Algorithm—Application Note, Jul. 2001, Edition 2 Philips Healthcare, USA. [cited by applicant]
Klein, H. U., Goldenberg I., & Moss, A. J., Risk Stratification for Implantable Cardioverter Defibrillator Therapy: The Role of the Wearable Cardioverter-Defibrillator, Clinical update, European Heart Journal, May 31, 2… [cited by applicant]
Lifecor LifeVest System Model WCD 3100 Operator's Manual, 2006, PN 20B0040 Rev FI, Zoll Lifecor Corporation, Pittsburgh, PA. [cited by applicant]
LifeVest Model 4000 Patient Manual, Zoll, 2009, PN 20B0047 Rev B. [cited by applicant]
Non-Final Office action issued on Dec. 21, 2020, to U.S. Appl. No. 16/307,990. [cited by applicant]
Non-Final Office Action issued on Mar. 27, 2020, to U.S. Appl. No. 16/038,007. [cited by applicant]
Non-final Office Action mailed on Feb. 16, 2022, to U.S. Appl. No. 16/554,410. [cited by applicant]
Olgin JE, Pletcher MJ, Vittinghoff E, et al., “Wearable Cardioverter-Defibrillator after Myocardial Infarction,” N Engl J Med Sep. 27, 2018; 379(13):1205-1215. [cited by applicant]
Pagan-Carlo, et al., “Encircling Overlapping Multipulse Shock Waveforms for Transthoracic Defibrillation,” JACC Journals, Dec. 1998, vol. 32 Issue 7, p. 2065-2071. [cited by applicant]
Schuhmann et al., “Experience with the wearable cardioverter defibrillator (WCD) in high risk cardiac patients from a German single center cohort”, Heart Rhythm 2016;13(5):S254. [cited by applicant]
Second Office Action issued on May 18, 2020, to CN Patent Application No. 2016111106350.1. [cited by applicant]
WCD Performance for Clinical Review, Sullivan et al., “A Novel Wearable Cardioverter Defibrillator With Reduced False Alarm Rate,” AHA 2017. [cited by applicant]
Zoll, LifeVest, Proven protection from Sudden Cardiac Death, issued Mar. 27, 2018, 4 pages. Pittsburgh PA, USA. [cited by applicant]